Centre de Radiothérapie Guillaume le Conquérant

Verified siteinfo

France 61 rue Denfert Rochereau, 76600 Le Havre, France

6 trials recruiting
Squamous cell carcinoma of head and neck · Anal squamous cell carcinoma · Hormone receptor positive HER2 negative breast cancer
Adult patients

About Specializations

Centre de Radiothérapie Guillaume le Conquérant in Le Havre, France specialises in clinical trials of conditions such as Squamous cell carcinoma of head and neck, Anal squamous cell carcinoma, Hormone receptor positive HER2 negative breast cancer, Hormone-refractory prostate cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neuro-Oncology

The medical center is at the forefront of neuro-oncology, focusing on innovative treatments for complex conditions such as brain metastases and brain radionecrosis. The center's research is pivotal in exploring advanced therapeutic options to improve patient outcomes.

Brain Metastases Management
Radionecrosis Treatment
Neurological Symptom Alleviation

Through rigorous clinical trials, the center is investigating the efficacy of combining bevacizumab with standard corticosteroid therapy, aiming to enhance the quality of life for patients suffering from these challenging conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

61 rue Denfert Rochereau76600 Le HavreFrance

Open in maps ↗

Recruiting now: 6 trials
Conditions studied: 10
Partner status: Verified site

More sites in Le Havre France

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

13 clinical trials

Squamous cell carcinoma of head and neck

Recruiting

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Ivonescimab
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Non-small cell lung cancer stage III

Recruiting

Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Rectal cancer+2

Recruiting

Study of Dostarlimab Combined with Short Course Radiotherapy for Locally Advanced Rectal Cancer Patients with Microsatellite Instability

Registered drugNo placebo

Study of Dostarlimab Combined with Short Course Radiotherapy for Locally Advanced Rectal Cancer Patients with Microsatellite Instability

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study of avelumab and cetuximab combination treatment after TPEx chemotherapy for patients with recurrent or metastatic head and neck cancer receiving first-line therapy

Registered drugNo placebo